# Efficacy and Tolerability of Beclomethasone Dipropionate/Formoterol Single Inhaler in Patients With Mild to Moderate Persistent Asthma

> **NCT00862264** · PHASE3 · COMPLETED · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 286 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Fixed combination Beclomethasone Dipropionate/Formoterol HFA 134a-pMDI

## Key facts

- **NCT ID:** NCT00862264
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08
- **Primary completion:** —
- **Final completion:** 2005-09
- **Target enrollment:** 286 (ACTUAL)
- **Last updated:** 2017-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00862264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00862264, "Efficacy and Tolerability of Beclomethasone Dipropionate/Formoterol Single Inhaler in Patients With Mild to Moderate Persistent Asthma". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00862264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*